| Target Antigen . | NCT# . | Phase . | Malignancies . | Signaling domain . | Estimated enrollment . | Sponsor . | Other information . |
|---|---|---|---|---|---|---|---|
| CD276 | NCT04864821 | EarlyI | CD276 positive advanced solid tumor (include lung cancer) | N/A | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| CEA | NCT02349724 | I | CEA positive cancers (include lung cancer) | N/A | 75 | Southwest Hospital, China | |
| NCT04348643 | I/II | Relapsed or refractory CEA positive cancers (include lung cancer) | N/A | 40 | Chongqing Precision Biotech Co., Ltd, China | ||
| DLL3 | NCT03392064 | I | Relapsed or refractory SCLC | N/A | 6 | Amgen | |
| EGFR | NCT01869166 | I/II | Chemotherapy refractory EGFR positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 60 | Chinese PLA General Hospital, China | |
| NCT02862028 | I/II | EGFR family member positive advanced solid tumors (include lung cancer) | N/A | 20 | Shanghai International Medical Center | HerinCAR-T cells expressing PD-1 antibodies | |
| NCT03638206 | I/II | Multiple malignancies (include lung cancer) | N/A | 73 | Shenzhen BinDebio Ltd, China | Anti-EGFR VIII CAR-T cells | |
| NCT04153799 | I | Advanced NSCLC | N/A | 11 | Sun Yat-sen University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| NCT05060796 | EarlyI | Advanced NSCLC | N/A | 11 | Second Affiliated Hospital of Guangzhou Medical University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| GPC3 | NCT02876978 | I | Recurrent or refractory lung squamous cell carcinoma | N/A | 20 | Carsgen Therapeutics, Ltd. | |
| NCT03198546 | I | GPC3 positive cancers (include squamous cell lung cancer) | 3rd/4th generation CAR-T | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | Anti-GPC3 and/or TGFβ | |
| HER2 | NCT01935843 | I/II | Chemotherapy refractory HER2 positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 10 | Chinese PLA General Hospital, China | |
| NCT02713984 | I/II | HER2 positive cancers (include lung cancer) | N/A | N/A | Southwest Hospotal, China | Reform CAR structure due to safety consideration | |
| NCT03740256 | I | Advanced HER2 positive solid tumors (include lung cancer) | N/A | 45 | Baylor College of Medicine, USA | HER2 specific CAR-T cells in combination with intra-tumor injection of oncolytic adenovirus CAdVEC | |
| MSLN | NCT02414269 | I/II | Malignant Pleural diseases (include NSCLC metastatic to the pleura) | N/A | 113 | Memorial Sloan Kettering Cancer Center, USA | iCasp9M28z T cells |
| NCT01583686 | I/II | MSLN positive metastatic cancers (include lung cancer) | N/A | 15 | National Cancer Institute (NCI), USA | Completed on 2018/12/17. 1 participant got stable disease, and 14 had progressive disease | |
| NCT04489862 | EarlyI | MSLN positive advanced solid tumors (include NSCLC) | N/A | 10 | Wuhan Union Hospital, China | MSLN-targeted CAR-T cells secreting PD-1 nanobodies | |
| NCT03054298 | I | MSLN positive cancers (include lung adenocarcinoma) | N/A | 18 | University of Pennsylvania, USA | Lentiviral transduced huCART-meso cells with or without lymphodepletion | |
| MUC1 | NCT02587689 | I/II | MUC1 positive advanced refractory solid tumors (include NSCLC) | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | |
| NCT03525782 | I/II | Lung neoplasm malignant and NSCLC | N/A | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical Univeristy, China | Anti-MUC1 CAR-T cells combining PD-1 knockout | |
| PD-L1 | NCT03330834 | I | PD-L1 positive advanced NSCLC | CD28/4-1BB/CD3ζ | 22 | Sun Yat-sen University, China | Ultimately only 1 participant who experienced severe CRS-induced interstitial pneumonia disease after the treatment |
| PD-L1, CD80/CD86 | NCT03060343 | EarlyI | Relapsed or refractory NSCLC | N/A | 10 | Yu Fenglei | Zeushield Cytotoxic T Lymphocytes |
| PSMA | NCT04633148 | I | PSMA expression positive cancers (include NSCLC) | N/A | 35 | Cellex Patient Treatment GmbH, Germany | T cells carrying universal CAR (UniCAR02-T) in combination with PSMA peptide target module (TMpPSMA) |
| ROR1 | NCT02706392 | I | ROR1 positive advanced malignancies (include metastatic/unresectable/Stage III/IV NSCLC) | N/A | 60 | Fred Hutchinson Cancer Research Center, USA | |
| TnMUC1 | NCT04025216 | I | TnMUC1 positive advanced cancers (include NSCLC) | N/A | 112 | Tmunity Therapeutics, USA | |
| HER2, MSLN, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR, B7-H3, Claudin 18.2 | NCT03198052 | I | Lung cancers | CD28/4-1BB/ OX-40/CD3ζ | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | |
| MAGE-A1, MAGE-A4, MUC1, GD2, MSLN | NCT03356808 | I/II | Lung cancers (SCLC and NSCLC) | N/A | 20 | Shenzhen Geno-Immune Medical Institute, China |
| Target Antigen . | NCT# . | Phase . | Malignancies . | Signaling domain . | Estimated enrollment . | Sponsor . | Other information . |
|---|---|---|---|---|---|---|---|
| CD276 | NCT04864821 | EarlyI | CD276 positive advanced solid tumor (include lung cancer) | N/A | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| CEA | NCT02349724 | I | CEA positive cancers (include lung cancer) | N/A | 75 | Southwest Hospital, China | |
| NCT04348643 | I/II | Relapsed or refractory CEA positive cancers (include lung cancer) | N/A | 40 | Chongqing Precision Biotech Co., Ltd, China | ||
| DLL3 | NCT03392064 | I | Relapsed or refractory SCLC | N/A | 6 | Amgen | |
| EGFR | NCT01869166 | I/II | Chemotherapy refractory EGFR positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 60 | Chinese PLA General Hospital, China | |
| NCT02862028 | I/II | EGFR family member positive advanced solid tumors (include lung cancer) | N/A | 20 | Shanghai International Medical Center | HerinCAR-T cells expressing PD-1 antibodies | |
| NCT03638206 | I/II | Multiple malignancies (include lung cancer) | N/A | 73 | Shenzhen BinDebio Ltd, China | Anti-EGFR VIII CAR-T cells | |
| NCT04153799 | I | Advanced NSCLC | N/A | 11 | Sun Yat-sen University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| NCT05060796 | EarlyI | Advanced NSCLC | N/A | 11 | Second Affiliated Hospital of Guangzhou Medical University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| GPC3 | NCT02876978 | I | Recurrent or refractory lung squamous cell carcinoma | N/A | 20 | Carsgen Therapeutics, Ltd. | |
| NCT03198546 | I | GPC3 positive cancers (include squamous cell lung cancer) | 3rd/4th generation CAR-T | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | Anti-GPC3 and/or TGFβ | |
| HER2 | NCT01935843 | I/II | Chemotherapy refractory HER2 positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 10 | Chinese PLA General Hospital, China | |
| NCT02713984 | I/II | HER2 positive cancers (include lung cancer) | N/A | N/A | Southwest Hospotal, China | Reform CAR structure due to safety consideration | |
| NCT03740256 | I | Advanced HER2 positive solid tumors (include lung cancer) | N/A | 45 | Baylor College of Medicine, USA | HER2 specific CAR-T cells in combination with intra-tumor injection of oncolytic adenovirus CAdVEC | |
| MSLN | NCT02414269 | I/II | Malignant Pleural diseases (include NSCLC metastatic to the pleura) | N/A | 113 | Memorial Sloan Kettering Cancer Center, USA | iCasp9M28z T cells |
| NCT01583686 | I/II | MSLN positive metastatic cancers (include lung cancer) | N/A | 15 | National Cancer Institute (NCI), USA | Completed on 2018/12/17. 1 participant got stable disease, and 14 had progressive disease | |
| NCT04489862 | EarlyI | MSLN positive advanced solid tumors (include NSCLC) | N/A | 10 | Wuhan Union Hospital, China | MSLN-targeted CAR-T cells secreting PD-1 nanobodies | |
| NCT03054298 | I | MSLN positive cancers (include lung adenocarcinoma) | N/A | 18 | University of Pennsylvania, USA | Lentiviral transduced huCART-meso cells with or without lymphodepletion | |
| MUC1 | NCT02587689 | I/II | MUC1 positive advanced refractory solid tumors (include NSCLC) | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | |
| NCT03525782 | I/II | Lung neoplasm malignant and NSCLC | N/A | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical Univeristy, China | Anti-MUC1 CAR-T cells combining PD-1 knockout | |
| PD-L1 | NCT03330834 | I | PD-L1 positive advanced NSCLC | CD28/4-1BB/CD3ζ | 22 | Sun Yat-sen University, China | Ultimately only 1 participant who experienced severe CRS-induced interstitial pneumonia disease after the treatment |
| PD-L1, CD80/CD86 | NCT03060343 | EarlyI | Relapsed or refractory NSCLC | N/A | 10 | Yu Fenglei | Zeushield Cytotoxic T Lymphocytes |
| PSMA | NCT04633148 | I | PSMA expression positive cancers (include NSCLC) | N/A | 35 | Cellex Patient Treatment GmbH, Germany | T cells carrying universal CAR (UniCAR02-T) in combination with PSMA peptide target module (TMpPSMA) |
| ROR1 | NCT02706392 | I | ROR1 positive advanced malignancies (include metastatic/unresectable/Stage III/IV NSCLC) | N/A | 60 | Fred Hutchinson Cancer Research Center, USA | |
| TnMUC1 | NCT04025216 | I | TnMUC1 positive advanced cancers (include NSCLC) | N/A | 112 | Tmunity Therapeutics, USA | |
| HER2, MSLN, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR, B7-H3, Claudin 18.2 | NCT03198052 | I | Lung cancers | CD28/4-1BB/ OX-40/CD3ζ | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | |
| MAGE-A1, MAGE-A4, MUC1, GD2, MSLN | NCT03356808 | I/II | Lung cancers (SCLC and NSCLC) | N/A | 20 | Shenzhen Geno-Immune Medical Institute, China |
| Target Antigen . | NCT# . | Phase . | Malignancies . | Signaling domain . | Estimated enrollment . | Sponsor . | Other information . |
|---|---|---|---|---|---|---|---|
| CD276 | NCT04864821 | EarlyI | CD276 positive advanced solid tumor (include lung cancer) | N/A | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| CEA | NCT02349724 | I | CEA positive cancers (include lung cancer) | N/A | 75 | Southwest Hospital, China | |
| NCT04348643 | I/II | Relapsed or refractory CEA positive cancers (include lung cancer) | N/A | 40 | Chongqing Precision Biotech Co., Ltd, China | ||
| DLL3 | NCT03392064 | I | Relapsed or refractory SCLC | N/A | 6 | Amgen | |
| EGFR | NCT01869166 | I/II | Chemotherapy refractory EGFR positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 60 | Chinese PLA General Hospital, China | |
| NCT02862028 | I/II | EGFR family member positive advanced solid tumors (include lung cancer) | N/A | 20 | Shanghai International Medical Center | HerinCAR-T cells expressing PD-1 antibodies | |
| NCT03638206 | I/II | Multiple malignancies (include lung cancer) | N/A | 73 | Shenzhen BinDebio Ltd, China | Anti-EGFR VIII CAR-T cells | |
| NCT04153799 | I | Advanced NSCLC | N/A | 11 | Sun Yat-sen University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| NCT05060796 | EarlyI | Advanced NSCLC | N/A | 11 | Second Affiliated Hospital of Guangzhou Medical University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| GPC3 | NCT02876978 | I | Recurrent or refractory lung squamous cell carcinoma | N/A | 20 | Carsgen Therapeutics, Ltd. | |
| NCT03198546 | I | GPC3 positive cancers (include squamous cell lung cancer) | 3rd/4th generation CAR-T | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | Anti-GPC3 and/or TGFβ | |
| HER2 | NCT01935843 | I/II | Chemotherapy refractory HER2 positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 10 | Chinese PLA General Hospital, China | |
| NCT02713984 | I/II | HER2 positive cancers (include lung cancer) | N/A | N/A | Southwest Hospotal, China | Reform CAR structure due to safety consideration | |
| NCT03740256 | I | Advanced HER2 positive solid tumors (include lung cancer) | N/A | 45 | Baylor College of Medicine, USA | HER2 specific CAR-T cells in combination with intra-tumor injection of oncolytic adenovirus CAdVEC | |
| MSLN | NCT02414269 | I/II | Malignant Pleural diseases (include NSCLC metastatic to the pleura) | N/A | 113 | Memorial Sloan Kettering Cancer Center, USA | iCasp9M28z T cells |
| NCT01583686 | I/II | MSLN positive metastatic cancers (include lung cancer) | N/A | 15 | National Cancer Institute (NCI), USA | Completed on 2018/12/17. 1 participant got stable disease, and 14 had progressive disease | |
| NCT04489862 | EarlyI | MSLN positive advanced solid tumors (include NSCLC) | N/A | 10 | Wuhan Union Hospital, China | MSLN-targeted CAR-T cells secreting PD-1 nanobodies | |
| NCT03054298 | I | MSLN positive cancers (include lung adenocarcinoma) | N/A | 18 | University of Pennsylvania, USA | Lentiviral transduced huCART-meso cells with or without lymphodepletion | |
| MUC1 | NCT02587689 | I/II | MUC1 positive advanced refractory solid tumors (include NSCLC) | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | |
| NCT03525782 | I/II | Lung neoplasm malignant and NSCLC | N/A | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical Univeristy, China | Anti-MUC1 CAR-T cells combining PD-1 knockout | |
| PD-L1 | NCT03330834 | I | PD-L1 positive advanced NSCLC | CD28/4-1BB/CD3ζ | 22 | Sun Yat-sen University, China | Ultimately only 1 participant who experienced severe CRS-induced interstitial pneumonia disease after the treatment |
| PD-L1, CD80/CD86 | NCT03060343 | EarlyI | Relapsed or refractory NSCLC | N/A | 10 | Yu Fenglei | Zeushield Cytotoxic T Lymphocytes |
| PSMA | NCT04633148 | I | PSMA expression positive cancers (include NSCLC) | N/A | 35 | Cellex Patient Treatment GmbH, Germany | T cells carrying universal CAR (UniCAR02-T) in combination with PSMA peptide target module (TMpPSMA) |
| ROR1 | NCT02706392 | I | ROR1 positive advanced malignancies (include metastatic/unresectable/Stage III/IV NSCLC) | N/A | 60 | Fred Hutchinson Cancer Research Center, USA | |
| TnMUC1 | NCT04025216 | I | TnMUC1 positive advanced cancers (include NSCLC) | N/A | 112 | Tmunity Therapeutics, USA | |
| HER2, MSLN, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR, B7-H3, Claudin 18.2 | NCT03198052 | I | Lung cancers | CD28/4-1BB/ OX-40/CD3ζ | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | |
| MAGE-A1, MAGE-A4, MUC1, GD2, MSLN | NCT03356808 | I/II | Lung cancers (SCLC and NSCLC) | N/A | 20 | Shenzhen Geno-Immune Medical Institute, China |
| Target Antigen . | NCT# . | Phase . | Malignancies . | Signaling domain . | Estimated enrollment . | Sponsor . | Other information . |
|---|---|---|---|---|---|---|---|
| CD276 | NCT04864821 | EarlyI | CD276 positive advanced solid tumor (include lung cancer) | N/A | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| CEA | NCT02349724 | I | CEA positive cancers (include lung cancer) | N/A | 75 | Southwest Hospital, China | |
| NCT04348643 | I/II | Relapsed or refractory CEA positive cancers (include lung cancer) | N/A | 40 | Chongqing Precision Biotech Co., Ltd, China | ||
| DLL3 | NCT03392064 | I | Relapsed or refractory SCLC | N/A | 6 | Amgen | |
| EGFR | NCT01869166 | I/II | Chemotherapy refractory EGFR positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 60 | Chinese PLA General Hospital, China | |
| NCT02862028 | I/II | EGFR family member positive advanced solid tumors (include lung cancer) | N/A | 20 | Shanghai International Medical Center | HerinCAR-T cells expressing PD-1 antibodies | |
| NCT03638206 | I/II | Multiple malignancies (include lung cancer) | N/A | 73 | Shenzhen BinDebio Ltd, China | Anti-EGFR VIII CAR-T cells | |
| NCT04153799 | I | Advanced NSCLC | N/A | 11 | Sun Yat-sen University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| NCT05060796 | EarlyI | Advanced NSCLC | N/A | 11 | Second Affiliated Hospital of Guangzhou Medical University, China | CXCR5-modified anti-EGFR CAR-T cells | |
| GPC3 | NCT02876978 | I | Recurrent or refractory lung squamous cell carcinoma | N/A | 20 | Carsgen Therapeutics, Ltd. | |
| NCT03198546 | I | GPC3 positive cancers (include squamous cell lung cancer) | 3rd/4th generation CAR-T | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | Anti-GPC3 and/or TGFβ | |
| HER2 | NCT01935843 | I/II | Chemotherapy refractory HER2 positive advanced solid tumors (include NSCLC) | CD28/4-1BB/CD3ζ | 10 | Chinese PLA General Hospital, China | |
| NCT02713984 | I/II | HER2 positive cancers (include lung cancer) | N/A | N/A | Southwest Hospotal, China | Reform CAR structure due to safety consideration | |
| NCT03740256 | I | Advanced HER2 positive solid tumors (include lung cancer) | N/A | 45 | Baylor College of Medicine, USA | HER2 specific CAR-T cells in combination with intra-tumor injection of oncolytic adenovirus CAdVEC | |
| MSLN | NCT02414269 | I/II | Malignant Pleural diseases (include NSCLC metastatic to the pleura) | N/A | 113 | Memorial Sloan Kettering Cancer Center, USA | iCasp9M28z T cells |
| NCT01583686 | I/II | MSLN positive metastatic cancers (include lung cancer) | N/A | 15 | National Cancer Institute (NCI), USA | Completed on 2018/12/17. 1 participant got stable disease, and 14 had progressive disease | |
| NCT04489862 | EarlyI | MSLN positive advanced solid tumors (include NSCLC) | N/A | 10 | Wuhan Union Hospital, China | MSLN-targeted CAR-T cells secreting PD-1 nanobodies | |
| NCT03054298 | I | MSLN positive cancers (include lung adenocarcinoma) | N/A | 18 | University of Pennsylvania, USA | Lentiviral transduced huCART-meso cells with or without lymphodepletion | |
| MUC1 | NCT02587689 | I/II | MUC1 positive advanced refractory solid tumors (include NSCLC) | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | |
| NCT03525782 | I/II | Lung neoplasm malignant and NSCLC | N/A | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical Univeristy, China | Anti-MUC1 CAR-T cells combining PD-1 knockout | |
| PD-L1 | NCT03330834 | I | PD-L1 positive advanced NSCLC | CD28/4-1BB/CD3ζ | 22 | Sun Yat-sen University, China | Ultimately only 1 participant who experienced severe CRS-induced interstitial pneumonia disease after the treatment |
| PD-L1, CD80/CD86 | NCT03060343 | EarlyI | Relapsed or refractory NSCLC | N/A | 10 | Yu Fenglei | Zeushield Cytotoxic T Lymphocytes |
| PSMA | NCT04633148 | I | PSMA expression positive cancers (include NSCLC) | N/A | 35 | Cellex Patient Treatment GmbH, Germany | T cells carrying universal CAR (UniCAR02-T) in combination with PSMA peptide target module (TMpPSMA) |
| ROR1 | NCT02706392 | I | ROR1 positive advanced malignancies (include metastatic/unresectable/Stage III/IV NSCLC) | N/A | 60 | Fred Hutchinson Cancer Research Center, USA | |
| TnMUC1 | NCT04025216 | I | TnMUC1 positive advanced cancers (include NSCLC) | N/A | 112 | Tmunity Therapeutics, USA | |
| HER2, MSLN, Lewis-Y, PSCA, MUC1, GPC3, AXL, EGFR, B7-H3, Claudin 18.2 | NCT03198052 | I | Lung cancers | CD28/4-1BB/ OX-40/CD3ζ | 30 | Second Affiliated Hospital of Guangzhou Medical University, China | |
| MAGE-A1, MAGE-A4, MUC1, GD2, MSLN | NCT03356808 | I/II | Lung cancers (SCLC and NSCLC) | N/A | 20 | Shenzhen Geno-Immune Medical Institute, China |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
